A Class of Allosteric Caspase Inhibitors Identified by High-Throughput Screening

Molecular Cell

Volumn 47, Issue 4, 2012, Pages 585-595

  Feldman, Taya ^a   Kabaleeswaran, Venkataraman ^b   Jang, Se Bok ^b,c   Antczak, Christophe ^a   Djaballah, Hakim ^a   Wu, Hao ^b   Jiang, Xuejun ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c Pusan National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 7; CASPASE 8; CASPASE 9; CASPASE INHIBITOR; COMP A; COMP B; COMP C; COMP D; CYTOCHROME C; CYTOKINE; ENZYME ACTIVATOR; INTERLEUKIN 1BETA CONVERTING ENZYME; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL TYPE; CHEMICAL ANALYSIS; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; DIMERIZATION; ENZYME ACTIVE SITE; HIGH THROUGHPUT SCREENING; KINETICS; MACROPHAGE; MUTAGENESIS;

AMINO ACID SEQUENCE; ANTI-INFLAMMATORY AGENTS; APOPTOSIS; CASPASE INHIBITORS; CASPASES; CATALYTIC DOMAIN; CELL LINE; CRYSTALLOGRAPHY, X-RAY; CYTOCHROMES C; ENZYME ACTIVATION; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INTERLEUKINS; KINETICS; MOLECULAR SEQUENCE DATA; MUTAGENESIS; PROTEIN MULTIMERIZATION;

EID: 84865389577     PISSN: 10972765     EISSN: 10974164     Source Type: Journal    
DOI: 10.1016/j.molcel.2012.06.007     Document Type: Article

References (53)

1. Acehan D., Jiang X., Morgan D.G., Heuser J.E., Wang X., Akey C.W. Three-dimensional structure of the apoptosome: implications for assembly, procaspase-9 binding, and activation. Mol. Cell 2002, 9:423-432.
2. Agniswamy J., Fang B., Weber I.T. Conformational similarity in the activation of caspase-3 and -7 revealed by the unliganded and inhibited structures of caspase-7. Apoptosis 2009, 14:1135-1144.
3. Antczak C., Shum D., Escobar S., Bassit B., Kim E., Seshan V.E., Wu N., Yang G., Ouerfelli O., Li Y.M., et al. High-throughput identification of inhibitors of human mitochondrial peptide deformylase. J. Biomol. Screen. 2007, 12:521-535.
4. Baici A. The specific velocity plot. A graphical method for determining inhibition parameters for both linear and hyperbolic enzyme inhibitors. Eur. J. Biochem. 1981, 119:9-14.
5. Boatright K.M., Renatus M., Scott F.L., Sperandio S., Shin H., Pedersen I.M., Ricci J.E., Edris W.A., Sutherlin D.P., Green D.R., Salvesen G.S. A unified model for apical caspase activation. Mol. Cell 2003, 11:529-541.
6. Chai J., Wu Q., Shiozaki E., Srinivasula S.M., Alnemri E.S., Shi Y. Crystal structure of a procaspase-7 zymogen: mechanisms of activation and substrate binding. Cell 2001, 107:399-407.
7. Garrido C., Galluzzi L., Brunet M., Puig P.E., Didelot C., Kroemer G. Mechanisms of cytochrome c release from mitochondria. Cell Death Differ. 2006, 13:1423-1433.
8. Glover C.J., Hite K., DeLosh R., Scudiero D.A., Fivash M.J., Smith L.R., Fisher R.J., Wu J.W., Shi Y., Kipp R.A., et al. A high-throughput screen for identification of molecular mimics of Smac/DIABLO utilizing a fluorescence polarization assay. Anal. Biochem. 2003, 320:157-169.
9. Green D.R., Reed J.C. Mitochondria and apoptosis. Science 1998, 281:1309-1312.
10. Hannon M.J. Metal-based anticancer drugs: From a past anchored in platinum chemistry to a post-genomic future of diverse chemistry and biology. Pure Appl. Chem. 2007, 79:2243-2261.
11. Hardy J.A., Wells J.A. Dissecting an allosteric switch in caspase-7 using chemical and mutational probes. J. Biol. Chem. 2009, 284:26063-26069.
12. Hardy J.A., Lam J., Nguyen J.T., O'Brien T., Wells J.A. Discovery of an allosteric site in the caspases. Proc. Natl. Acad. Sci. USA 2004, 101:12461-12466.
13. He S., Wang L., Miao L., Wang T., Du F., Zhao L., Wang X. Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-α. Cell 2009, 137:1100-1111.
14. Hotchkiss R.S., Nicholson D.W. Apoptosis and caspases regulate death and inflammation in sepsis. Nat. Rev. Immunol. 2006, 6:813-822.
15. Ivachtchenko A.V., Okun I., Tkachenko S.E., Kiselyov A.S., Ivanenkov Y.A., Balakin K.V. Nonpeptide Small Molecule Inhibitors of Caspases. Design of Caspase Inhibitors as Potential Clinical Agents 2009, 93-122. CRC Press, Boca Raton, FL. T. O'Brien, S. Linton (Eds.).
16. Jiang X., Wang X. Cytochrome c promotes caspase-9 activation by inducing nucleotide binding to Apaf-1. J. Biol. Chem. 2000, 275:31199-31203.
17. Jiang X.J., Wang X.D. Cytochrome C-mediated apoptosis. Annu. Rev. Biochem. 2004, 73:87-106.
18. Kabsch W. Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants. J. Appl. Cryst. 1993, 26:795-800.
19. Kim H.E., Du F., Fang M., Wang X. Formation of apoptosome is initiated by cytochrome c-induced dATP hydrolysis and subsequent nucleotide exchange on Apaf-1. Proc. Natl. Acad. Sci. USA 2005, 102:17545-17550.
20. Li L., Thomas R.M., Suzuki H., De Brabander J.K., Wang X.D., Harran P.G. A small molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell death. Science 2004, 305:1471-1474.
21. Li Z., Jo J., Jia J.M., Lo S.C., Whitcomb D.J., Jiao S., Cho K., Sheng M. Caspase-3 activation via mitochondria is required for long-term depression and AMPA receptor internalization. Cell 2010, 141:859-871.
22. MacPherson I.S., Murphy M.E. Type-2 copper-containing enzymes. Cell. Mol. Life Sci. 2007, 64:2887-2899.
23. Martinon F., Tschopp J. Inflammatory caspases and inflammasomes: master switches of inflammation. Cell Death Differ. 2007, 14:10-22.
24. Martinon F., Burns K., Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol. Cell 2002, 10:417-426.
25. McCoy A.J., Grosse-Kunstleve R.W., Adams P.D., Winn M.D., Storoni L.C., Read R.J. Phaser crystallographic software. J. Appl. Cryst. 2007, 40:658-674.
26. Nor Y.M. Ecotoxicity of copper to aquatic biota: a review. Environ. Res. 1987, 43:274-282.
27. (L) complex inhibits RIPK3-dependent necrosis. Nature 2011, 471:363-367.
28. Oltersdorf T., Elmore S.W., Shoemaker A.R., Armstrong R.C., Augeri D.J., Belli B.A., Bruncko M., Deckwerth T.L., Dinges J., Hajduk P.J., et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005, 435:677-681.
29. Otwinowski Z., Minor W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 1997, 276:307-326.
30. Peter M.E., Krammer P.H. The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ. 2003, 10:26-35.
31. Pop C., Salvesen G.S. Human caspases: activation, specificity, and regulation. J. Biol. Chem. 2009, 284:21777-21781.
32. Reed J.C. Apoptosis-targeted therapies for cancer. Cancer Cell 2003, 3:17-22.
33. Renatus M., Stennicke H.R., Scott F.L., Liddington R.C., Salvesen G.S. Dimer formation drives the activation of the cell death protease caspase 9. Proc. Natl. Acad. Sci. USA 2001, 98:14250-14255.
34. Riedl S.J., Shi Y.G. Molecular mechanisms of caspase regulation during apoptosis. Nat. Rev. Mol. Cell Biol. 2004, 5:897-907.
35. Riedl S.J., Fuentes-Prior P., Renatus M., Kairies N., Krapp S., Huber R., Salvesen G.S., Bode W. Structural basis for the activation of human procaspase-7. Proc. Natl. Acad. Sci. USA 2001, 98:14790-14795.
36. Rodriguez J., Lazebnik Y. Caspase-9 and APAF-1 form an active holoenzyme. Genes Dev. 1999, 13:3179-3184.
37. Scheer J.M., Romanowski M.J., Wells J.A. A common allosteric site and mechanism in caspases. Proc. Natl. Acad. Sci. USA 2006, 103:7595-7600.
38. Schweizer A., Briand C., Grutter M.G. Crystal structure of caspase-2, apical initiator of the intrinsic apoptotic pathway. J. Biol. Chem. 2003, 278:42441-42447.
39. Schweizer A., Roschitzki-Voser H., Amstutz P., Briand C., Gulotti-Georgieva M., Prenosil E., Binz H.K., Capitani G., Baici A., Plückthun A., Grütter M.G. Inhibition of caspase-2 by a designed ankyrin repeat protein: specificity, structure, and inhibition mechanism. Structure 2007, 15:625-636.
40. Seideman J.H., Shum D., Djaballah H., Scheinberg D.A. A high-throughput screen for alpha particle radiation protectants. Assay Drug Dev. Technol. 2010, 8:602-614.
41. Shelton C.C., Tian Y., Shum D., Radu C., Djaballah H., Li Y.M. A miniaturized 1536-well format gamma-secretase assay. Assay Drug Dev. Technol. 2009, 7:461-470.
42. Shi Y.G. Mechanisms of caspase activation and inhibition during apoptosis. Mol. Cell 2002, 9:459-470.
43. Shum D., Radu C., Kim E., Cajuste M., Shao Y., Seshan V.E., Djaballah H. A high density assay format for the detection of novel cytotoxic agents in large chemical libraries. J. Enzyme Inhib. Med. Chem. 2008, 23:931-945.
44. Srinivasula S.M., Ahmad M., Fernandes-Alnemri T., Alnemri E.S. Autoactivation of procaspase-9 by Apaf-1-mediated oligomerization. Mol. Cell 1998, 1:949-957.
45. Tait S.W., Parsons M.J., Llambi F., Bouchier-Hayes L., Connell S., Muñoz-Pinedo C., Green D.R. Resistance to caspase-independent cell death requires persistence of intact mitochondria. Dev. Cell 2010, 18:802-813.
46. Talanian R.V., Brady K.D., Cryns V.L. Caspases as targets for anti-inflammatory and anti-apoptotic drug discovery. J. Med. Chem. 2000, 43:3351-3371.
47. Vandenabeele P., Declercq W., Van Herreweghe F., Vanden Berghe T. The role of the kinases RIP1 and RIP3 in TNF-induced necrosis. Sci. Signal. 2010, 3:re4.
48. Vaux D.L., Korsmeyer S.J. Cell death in development. Cell 1999, 96:245-254.
49. Vogt A., Cooley K.A., Brisson M., Tarpley M.G., Wipf P., Lazo J.S. Cell-active dual specificity phosphatase inhibitors identified by high-content screening. Chem. Biol. 2003, 10:733-742.
50. Yin Q., Park H.H., Chung J.Y., Lin S.C., Lo Y.C., da Graca L.S., Jiang X., Wu H. Caspase-9 holoenzyme is a specific and optimal procaspase-3 processing machine. Mol. Cell 2006, 22:259-268.
51. Youle R.J., Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat. Rev. Mol. Cell Biol. 2008, 9:47-59.
52. Yuan J.Y., Yankner B.A. Apoptosis in the nervous system. Nature 2000, 407:802-809.
53. Zou H., Li Y., Liu X., Wang X. An APAF-1.cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. J. Biol. Chem. 1999, 274:11549-11556.